Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
Vial Logo
Back to Resources
  • Videos

Obesity expert and researcher, Dr. Lawrence Cheskin MD, discusses how targeting adipose tissue is critical for treating obesity, positioning INHBE siRNA as a promising target to drive quality fat loss.

Discover Vial’s INHBE siRNA program: vial.com/inhbe-activin-e/

View on Linkedin

More Resources

Dr. JiaDe Yu, Chair of Dermatology and Associate Professor at Virginia Commonwealth University School of Medicine, highlights how dual inhibition of IL-13 and TSLP could advance care for patients with atopic dermatitis, delivering stronger efficacy than targeting either pathway alone.

Dr. Jason Fung: Treating obesity means more than weight loss – it’s about correcting metabolic disease. Vial’s INHBE siRNA can help obese and overweight populations avoid major health issues.

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, Emeritus Professor of Medicine at the University of Alberta, highlights INHBE as a promising new target for obesity, acting on both adipocytes and hepatocytes to drive fat-selective weight loss.

Connect with us.

Interested in receiving a proposal from Vial? Leave us a message and some of your contact info and we’ll be in touch with you shortly.

This field is for validation purposes and should be left unchanged.
Name(Required)
By submitting, you are agreeing to our terms and privacy policy

Contact Us

This field is for validation purposes and should be left unchanged.
Name(Required)
By submitting, you are agreeing to our terms and privacy policy